Genenta Science S.p.A. American Depositary Shares

Genenta Science reported positive survival metrics in its TEM-GBM study for glioblastoma patients, with 44% reaching 18-month survival and one patient surviving 39 months after treatment. The company also announced approximately $30 million in cash and short-term investments following a recent direct offering.

The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.